These innovative agents represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://fanniepcns525859.blogacep.com/44632094/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide